CCNA2 and breast carcinoma: In this study we evaluate the potential MGMT’s role in control of therapeutic, clinically relevant, cell cycle regulators involved in breast cancer oncogenesis (CDC2, TOP2A, AURKB, CDC20, KIF20A, Cyclin A2, Cyclin B2, Cyclin D1).